MADRIGAL PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
MDGL$432.79+8.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $198,693 | $100,019 |
| Restricted cash | 5,090 | 5,000 |
| Marketable securities | 784,866 | 826,232 |
| Trade receivables, net | 134,476 | 53,822 |
| Inventory | 74,841 | 34,068 |
| Prepaid expenses and other current assets | 47,804 | 13,786 |
| Total current assets | 1,245,770 | 1,032,927 |
| Property and equipment, net | 1,499 | 2,190 |
| Intangible assets, net | 7,381 | 4,729 |
| Right-of-use asset | 4,939 | 2,401 |
| Total assets | $1,259,589 | $1,042,247 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $48,878 | $43,599 |
| Accrued liabilities | 260,392 | 124,695 |
| Lease liabilities | 1,018 | 983 |
| Total current liabilities | 310,288 | 169,277 |
| Long term liabilities: | ||
| Loan payable, net of discount | 339,881 | 117,569 |
| Lease liabilities | 6,731 | 1,018 |
| Total long term liabilities | 346,612 | 118,587 |
| Total liabilities | 656,900 | 287,864 |
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at December 31, 2025 and December 31, 2024; 2,369,797 shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — |
| Common stock, par value $0.0001 per share authorized: 200,000,000 at December 31, 2025 and December 31, 2024; 22,842,073 and 22,004,679 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 2 | 2 |
| Additional paid-in-capital | 2,692,280 | 2,556,095 |
| Accumulated other comprehensive income | 873 | 468 |
| Accumulated deficit | (2,090,466) | (1,802,182) |
| Total stockholders’ equity | 602,689 | 754,383 |
| Total liabilities and stockholders’ equity | $1,259,589 | $1,042,247 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.